Safety and Effectiveness Study of Non-immunogenic Staphylokinase for Massive Pulmonary Embolism Treatment
Led by Supergene, LLC · Updated on 2026-07-06
20000
Participants Needed
14
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to study the safety and effectiveness of a drug called non-immunogenic staphylokinase in patients with massive pulmonary embolism, a serious condition involving blood clots in the lungs. The study builds on previous trials that found this drug to be as effective as alteplase with fewer major bleeding events, making it a promising emergency treatment option. The study is observational and focuses on patients receiving this drug in routine clinical practice.
Participants receive a single intravenous bolus dose of 15 mg non-immunogenic staphylokinase Fortelyzin4 regardless of body weight. This drug is easy to administer quickly in emergency situations and is used for treating massive pulmonary embolism since 2024. The study collects information on patients treated with this drug to assess outcomes in a real-world setting.
During the study, participants are monitored for outcomes such as all-cause mortality at 7 and 30 days after drug administration, hemodynamic collapse, recurrent pulmonary embolism, and pulmonary artery systolic pressure changes. Safety is closely observed, especially for bleeding events. The study runs from June 2025 to December 2027, with ongoing evaluation of participants following treatment in routine care.
CONDITIONS
Brief Title
Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism
Research Team
S
Sergey N. Tereschenko, MD, Prof.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Men and women aged 18 years and older
Confirmed diagnosis of massive pulmonary embolism using computer tomography
Signs of right ventricle overload or dysfunction combined with persistent arterial hypotension or shock
Symptoms started no more than 14 days before
Treatment with 15 mg single intravenous bolus of non-immunogenic staphylokinase
You will not qualify if you...
Increased risk of bleeding including recent or current extensive bleeding, intracranial hemorrhage, hemorrhagic stroke within 6 months
History of central nervous system diseases such as neoplasms or aneurysms
Intracranial or spinal surgery within last 2 months
Major surgery or trauma within previous 4 weeks
Recent puncture of incompressible blood vessels
Severe liver diseases including liver failure, cirrhosis, portal hypertension, active hepatitis
Confirmed gastric or duodenal ulcer within last 3 months
Neoplasm with increased bleeding risk
Use of Dabigatran without prior idarucizumab
Arterial aneurysms or developmental artery/vein defects
Acute pancreatitis
Bacterial endocarditis or pericarditis
Suspected aortic dissecting aneurysm
Any other condition with high bleeding risk per investigator
Pregnancy or lactation
Known allergy to non-immunogenic recombinant staphylokinase
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Single administration
Participants receive a single intravenous bolus dose of 15 mg non-immunogenic staphylokinase as part of their routine care for massive pulmonary embolism.
1 treatment visit
Follow-up
Duration - 30 days
Participants are monitored for safety and outcomes including survival, bleeding events, and lung artery pressure for up to 30 days after treatment.
Regular clinical assessments during follow-up period
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Study Comparing Outcomes of Catheter-Based Treatments for Acute Pulmonary Embolism in Hong Kong
Randomized Study Comparing Early Catheter-Based Treatment Plus Standard Care Versus Standard Care Alone for High Risk Pulmonary Embolism
Safety and Effectiveness Study of Non-immunogenic Staphylokinase for Massive Pulmonary Embolism Treatment
Registry Collecting Data on Catheter-Based Interventions for Acute Pulmonary Embolism
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.
Alexander I Kirienko, Stanislav G Leontyev, Sergey N Tereschenko...